Quadrivalent vaccine mod humant papillomvirus til forebyggelse af svaere celleforandringer på livmoderhalsen

Translated title of the contribution: Quadrivalent HPV 6/11/16/18 vaccine

Susanne Krüger Kjaer, Erik Søgård Andersen, Henning Djursing, Tom Hansen, Jens Jørgen Jørgensen, Lisbeth Nilas, Bent S Ottesen, Lone Keld Petersen, Steen Grove Thomsen, Kim Toftager-Larsen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

This randomized, double-blind study included 12,167 women who received three doses of quadrivalent HPV 6/11/16/18 vaccine or placebo (day 1, month 2, and month 6). The participants were followed for an average of 3 years. The vaccine prevented 98% of CIN2, CIN3 and adenocarcinoma in situ related to HPV 16 or HPV 18 among women not previously exposed to these types, and 44% among all women (i.e. both those with and without previous infection). The vaccine efficacy against all high-grade cervical lesions, independent of causal HPV type, was estimated to 17%.

Translated title of the contributionQuadrivalent HPV 6/11/16/18 vaccine
Original languageDanish
JournalUgeskrift for Laeger
Volume169
Issue number46
Pages (from-to)3971-4
Number of pages4
ISSN0041-5782
Publication statusPublished - 12. Nov 2007

Fingerprint Dive into the research topics of 'Quadrivalent HPV 6/11/16/18 vaccine'. Together they form a unique fingerprint.

  • Cite this

    Kjaer, S. K., Andersen, E. S., Djursing, H., Hansen, T., Jørgensen, J. J., Nilas, L., Ottesen, B. S., Petersen, L. K., Thomsen, S. G., & Toftager-Larsen, K. (2007). Quadrivalent vaccine mod humant papillomvirus til forebyggelse af svaere celleforandringer på livmoderhalsen. Ugeskrift for Laeger, 169(46), 3971-4.